Skip to main content

Advertisement

Log in

Too Big to Fail: Successful Resection of a Large Hepatocellular Carcinoma with Portal Tumor Thrombus

  • Stanford Multidisciplinary Seminars
  • Published:
Digestive Diseases and Sciences Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

References

  1. Li L, Wang HQ, Wang Q, Yang J, Yang JY. Anterior vs conventional approach hepatectomy for large liver cancer: a meta-analysis. World J Gastroenterol. 2014;20:17235–17243. https://doi.org/10.3748/wjg.v20.i45.17235.

    Article  PubMed  PubMed Central  Google Scholar 

  2. Cancer Today. https://gco.iarc.fr/today/home. Accessed September 17, 2020.

  3. Villanueva A. Hepatocellular carcinoma. N Engl J Med. 2019;380:1450–1462. https://doi.org/10.1056/NEJMra1713263.

    Article  CAS  PubMed  Google Scholar 

  4. Zucman-Rossi J, Villanueva A, Nault JC, Llovet JM. Genetic landscape and biomarkers of hepatocellular carcinoma. Gastroenterology. 2015;149:1226-1239.e4. https://doi.org/10.1053/j.gastro.2015.05.061.

    Article  CAS  PubMed  Google Scholar 

  5. Chernyak V, Fowler KJ, Kamaya A, Kielar AZ, Elsayes KM, Bashir MR, Kono Y, Do RK, et al. Liver imaging reporting and data system (LI-RADS) version 2018: imaging of hepatocellular carcinoma in at-risk patients. Radiology. 2018;289:816–830. https://doi.org/10.1148/radiol.2018181494.

    Article  PubMed  Google Scholar 

  6. Young AL, Malik HZ, Abu-Hilal M, Guthrie JA, Wyatt J, Prasad KR, Toogood GJ, Lodge JPA. Large hepatocellular carcinoma: time to stop preoperative biopsy. J Am Coll Surg. 2007;205:453–462. https://doi.org/10.1016/j.jamcollsurg.2007.04.033.

    Article  PubMed  Google Scholar 

  7. Llovet JM, Brú C, Bruix J. Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin Liver Dis. 1999;19:329–337. https://doi.org/10.1055/s-2007-1007122.

    Article  CAS  PubMed  Google Scholar 

  8. Tsilimigras DI, Bagante F, Sahara K, Moris D, Hyer JM, Wu L, Ratti F, Marques HP, et al. Prognosis after resection of Barcelona Clinic Liver Cancer (BCLC) stage 0, A, and B hepatocellular carcinoma: a comprehensive assessment of the current BCLC classification. Ann Surg Oncol. 2019;26:3693–3700. https://doi.org/10.1245/s10434-019-07580-9.

    Article  PubMed  Google Scholar 

  9. Mazzaferro V, Regalia E, Doci R, Andreola S, Pulvirenti A, Bozzetti F, Montalto F, Ammatuna M, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med. 1996; https://doi.org/10.1056/NEJM199603143341104.

    Article  PubMed  Google Scholar 

  10. Shah SA, Wei AC, Cleary SP, Yang I, McGilvray ID, Gallinger S, Grant DR, Greig PD. Prognosis and results after resection of very large (≥ 10 cm) hepatocellular carcinoma. J Gastrointest Surg. 2007;11:589–595. https://doi.org/10.1007/s11605-007-0154-7.

    Article  PubMed  Google Scholar 

  11. Liu CL, Fan ST, Lo CM, Poon RTP, Wong J. Anterior approach for major right hepatic resection for large hepatocellular carcinoma. Ann Surg. 2000;232:25–31. https://doi.org/10.1097/00000658-200007000-00004.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Shi J, Lai ECH, Li N, Guo WX, Xue J, Lau WY, Wu MC, Cheng SQ. Surgical treatment of hepatocellular carcinoma with portal vein tumor thrombus. Ann Surg Oncol. 2010; https://doi.org/10.1245/s10434-010-0940-4.

    Article  PubMed  PubMed Central  Google Scholar 

  13. Yang SL, Liu LP, Yang S, Liu L, Ren JW, Fang X, Chen GG, Lai PBS. Preoperative serum α-fetoprotein and prognosis after hepatectomy for hepatocellular carcinoma. Br J Surg. 2016;103:716–724. https://doi.org/10.1002/bjs.10093.

    Article  CAS  PubMed  Google Scholar 

  14. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc J-F, de Oliveira AC, Santoro A, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008;359:378–390. https://doi.org/10.1056/NEJMoa0708857.

    Article  CAS  PubMed  Google Scholar 

  15. Kudo M, Finn RS, Qin S, Han KH, Ikeda K, Piscaglia F, Baron A, Park JW, et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. Lancet. 2018;391:1163–1173. https://doi.org/10.1016/S0140-6736(18)30207-1.

    Article  CAS  PubMed  Google Scholar 

  16. Bruix J, Qin S, Merle P, Granito A, Huang YH, Bodoky G, Pracht M, Yokosuka O, et al. Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2017;389:56–66. https://doi.org/10.1016/S0140-6736(16)32453-9.

    Article  CAS  PubMed  Google Scholar 

  17. Zhu AX, Park JO, Ryoo BY, Yen CJ, Poon R, Pastorelli D, Blanc JF, Chung HC, et al. Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trial. Lancet Oncol. 2015;16:859–870. https://doi.org/10.1016/S1470-2045(15)00050-9.

    Article  CAS  PubMed  Google Scholar 

  18. Finn RS, Qin S, Ikeda M, Galle PR, Ducreux M, Kim TY, Kudo M, Breder V, et al. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. N Engl J Med. 2020;382:1894–1905. https://doi.org/10.1056/NEJMoa1915745.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgments

This work has not previously or concurrently been submitted for publication. The work was presented as part of the Stanford Multidisciplinary Seminar Series in Digestive Sciences on September 2, 2020.

Author information

Authors and Affiliations

Authors

Contributions

All authors contributed to research design, data collection, analysis, manuscript writing, and critical revision.

Corresponding author

Correspondence to Brendan C. Visser.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Bergquist, J.R., Li, A.Y., Javadi, C.S. et al. Too Big to Fail: Successful Resection of a Large Hepatocellular Carcinoma with Portal Tumor Thrombus. Dig Dis Sci 66, 1797–1801 (2021). https://doi.org/10.1007/s10620-020-06682-9

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10620-020-06682-9

Keywords

Navigation